

Metabolic Surgery for Adult Obesity: Common Questions and Answers

Elaine Seaton Banerjee, MD, MPH, and Robin Schroeder, MD, University of South Florida Morsani College of Medicine, Tampa, Florida; and Lehigh Valley Health Network, Allentown, Pennsylvania

T. Daniel Harrison, DO, Lehigh Valley Health Network, Allentown, Pennsylvania

In 2019, approximately 256,000 metabolic surgery procedures were performed in the United States, a 32% increase since 2014. The most common procedures are the laparoscopic sleeve gastrectomy and the Roux-en-Y gastric bypass. Choice of procedure depends on concurrent medical conditions, patient preference, and expertise of the surgeon. These procedures have a mortality risk of 0.2% to 0.3%. On average, weight loss of 30 to 50 kg (66 to 110 lb), or a 20% to 30% reduction in total body weight, is achieved, although most patients will experience some weight regain three to 10 years after surgery. In patients who have had metabolic surgery, all-cause mortality is reduced by 30% to 45% at two to 15 years postsurgery compared with patients with obesity who did not have surgery. Approximately 70% of surgical patients achieve remission of type 2 diabetes mellitus, and more than 30% of surgical patients maintain remission at 10 years. Other obesity-related conditions are also greatly reduced, and quality of life improves. Postoperatively, patients require standardized nutritional supplementation and surveillance. Persistent changes in diet, such as consuming protein first at every meal, regular physical activity, and ongoing attention to behavior change are critical for the success of the patient after metabolic surgery. Common adverse outcomes include surgical complications, nutritional deficiencies, bone density loss, dumping syndrome, gastroesophageal reflux disease, and loose skin. The family physician is well positioned to counsel patients about metabolic surgical options and the risks and benefits of surgery and to provide long-term support and medical management for postsurgery patients. (*Am Fam Physician*. 2022;105(6):593-601. Copyright © 2022 American Academy of Family Physicians.)



Illustration by Jennifer Fairman

Obesity is a disease that has serious physical, psychological, and economic implications for patients and the health care system.¹ When defined by a body mass index (BMI) of 30 kg per m² and above, 42% of the current U.S. adult population have obesity, and 9% have class 3 obesity (BMI greater than or equal to 40 kg per m²).² The primary care office can be a supportive, nonjudgmental environment for patients with obesity by connecting them with evidence-based treatment resources. The Strategies to Overcome & Prevent

(STOP) Obesity Alliance (<https://stop.publichealth.gwu.edu>) provides resources for physicians,³ and the Obesity Action Coalition (<https://www.obesityaction.org>) provides resources for patients and physicians.⁴

On average, patients who have metabolic surgery lose 26 kg (57 lb) more than those with nonsurgical weight loss and are five times more likely to experience remission of diabetes mellitus.⁵ According to the American Society for Metabolic and Bariatric Surgery, approximately 256,000 metabolic surgeries were performed in the United States in 2019, a 32% increase in five years.⁶ The term metabolic surgery is now preferred because of the metabolic effects of surgical procedures beyond weight loss.⁷

What Procedures Are Commonly Performed?

As of 2019, laparoscopic sleeve gastrectomy (60%) and Roux-en-Y gastric bypass (18%) were the most common metabolic surgeries.⁶ The choice of procedure depends on patient preference, the expertise of the surgeon and surgical center, and risk stratification.⁷

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 582.

Author disclosure: A public database shows that Dr. Harrison has attended an industry-sponsored training course for robotic-assisted surgery; this is considered standard practice and is required to use the surgical platform in bariatric surgery. He has not served as a speaker or consultant for this company. Drs. Banerjee and Schroeder have no relevant financial relationships.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Metabolic surgery should be included in counseling for obesity treatment options for eligible patients (BMI of 40 kg per m ² or BMI of 35 kg per m ² and one or more obesity-related conditions). ⁷	C	Recommendation from consensus guideline
After metabolic surgery, patients should avoid nonsteroidal anti-inflammatory drugs and take daily vitamin supplements indefinitely. ⁷	C	Recommendation from consensus guideline
Following metabolic surgery, laboratory studies should be completed quarterly for the first postsurgical year, then annually. ⁷	C	Recommendation from consensus guideline
Patients should be counseled to delay pregnancy for at least 12 to 24 months after metabolic surgery. ^{7,19}	C	Recommendation from consensus guidelines
Metabolic surgery is an effective treatment option for type 2 diabetes mellitus. ²⁷⁻³¹	A	Consistent findings from randomized controlled trial, observational study, and meta-analyses
Initial treatment for dumping syndrome includes eating small, frequent meals; avoiding fluids with meals; and avoiding rapidly absorbed sugars. ⁵⁴	C	Recommendation from consensus guideline
Roux-en-Y gastric bypass is better than sleeve gastrectomy for patients with gastroesophageal reflux disease. ^{32,54,55}	A	Consistent findings from a meta-analysis of randomized controlled trials and observational studies

BMI = body mass index.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

EVIDENCE SUMMARY

The sleeve gastrectomy procedure resects most of the body and all of the fundus of the stomach, creating a long, narrow, tubular stomach (*Figure 1*⁸). Single anastomosis duodenal-ileal bypass with sleeve was endorsed by the American Society for Metabolic and Bariatric Surgery in 2020 and will likely become more prevalent in the coming years.⁹ Single anastomosis duodenal-ileal bypass with sleeve adds a bypass of the duodenum to traditional sleeve, which can be performed as a single procedure or as a revision to a prior sleeve gastrectomy (*Figure 2*).


In Roux-en-Y gastric bypass, a small gastric pouch is formed by dividing the upper stomach and joining it with the resected end of the jejunum so that food bypasses the stomach and upper small bowel, thereby restricting the size of the stomach and causing some malabsorption (*Figure 3*⁸).

Family physicians may see patients who have a laparoscopic adjustable gastric band (*Figure 4*⁸). The adjustable gastric band now accounts for less than 1% of procedures because of a higher complication rate and lesser weight loss.^{6,10}

How Does Metabolic Surgery Lead to Weight Loss and Improvement in Type 2 Diabetes?

*Weight loss and improvement in type 2 diabetes result from complicated neuroendocrine changes that lead to decreased hunger, increased satiety, and improved glycemic control combined with a physically smaller stomach.*¹¹

FIGURE 1



Laparoscopic sleeve gastrectomy involves removing the fundus and most of the body of the stomach, creating a narrow, "sleeve-like" gastric structure.

Illustration by Dave Klemm

Reprinted with permission from Schroeder R, Harrison TD, McGraw SL. Treatment of adult obesity with bariatric surgery. *Am Fam Physician*. 2016;93(1):34.

EVIDENCE SUMMARY

Procedures were previously conceptualized as restrictive (create a smaller stomach), malabsorptive (bypass normal anatomy), or a combination, resulting in a calorie deficit. However, improvements in blood glucose levels and other obesity-related conditions occur earlier than can be fully explained by weight loss. Research indicates that the mechanisms of action include multiple physiologic variables that impact a complex neuroendocrine system involving the gut, central and peripheral nervous systems, and adipocytes to regulate energy homeostasis.¹¹ Glucagon-like peptide-1 and peptide YY increase after Roux-en-Y gastric bypass and sleeve gastrectomy.¹¹ Glucagon-like peptide-1 enhances insulin secretion, whereas peptide YY increases satiety and delays gastric emptying. Other hormones

affected by metabolic surgery include insulin, ghrelin, leptin, C-reactive protein, interleukin-6, tumor necrosis factor- α , and adiponectin.^{11,12}

Who Is Eligible for Metabolic Surgery?

According to the 2019 guidelines co-sponsored by the American Association of Clinical Endocrinologists, American College of Endocrinology, the Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists, patients with a BMI greater than or equal to 40 kg per m² or a BMI greater than or equal to 35 kg per m² plus one or more severe obesity-related conditions are generally eligible for metabolic surgery.⁷ Patients with a BMI of 30 to 34.9 kg per m² and type 2 diabetes with inadequate glycemic control despite optimal lifestyle and medical therapy should also be considered.⁷

EVIDENCE SUMMARY

Despite limitations in assessing adiposity in individuals with high muscle mass, women, older adults, and different races,¹³ BMI continues to be commonly used for determining surgical eligibility. Selection and exclusion criteria are listed in Table 1.⁷ Common exclusion criteria are current tobacco, alcohol, and illicit drug use.⁷


What Are the Key Components of the Presurgical Evaluation?

The presurgical evaluation must include a comprehensive medical history, psychosocial history, physical examination, appropriate laboratory testing, and evaluation for exclusion criteria.⁷

EVIDENCE SUMMARY


Presurgical evaluation requires teamwork between the primary care physician, surgeon, nutritionist, and behavioral health specialist to identify and manage conditions that may affect surgical risk, morbidity, and long-term weight-loss maintenance.⁷ Guidelines for evaluation and presurgical support are summarized in Table 2.⁷ Appropriate cancer screening should be conducted before surgery.⁷ Preoperative weight loss may improve the technical aspects of the surgery by decreasing liver volume⁷ and is associated with shorter hospital stay and lower risk of complications.^{14,15} However, insurance-mandated preoperative weight-loss programs were not associated with differences in weight loss, complications, or 30-day mortality.¹⁶

FIGURE 2




Single anastomosis duodenal-ileal bypass with sleeve. This newer bariatric procedure incorporates both a sleeve gastrectomy and a duodeno-ileostomy to bypass a portion of the small intestine. Often performed as a single procedure, the duodenal-ileal bypass may also be added as a revision to a prior sleeve gastrectomy.

FIGURE 3



A



B

(A) Stomach, duodenum, and jejunum before metabolic surgery. (B) After Roux-en-Y gastric bypass, food is transferred from a small gastric pouch into the middle portion of the small intestine.

Illustration by Dave Klemm

Reprinted with permission from Schroeder R, Harrison TD, McGraw SL. Treatment of adult obesity with bariatric surgery. Am Fam Physician. 2016;93(1):34.


After Metabolic Surgery, What Should the Patient Do and Expect?

After metabolic surgery, patients should avoid nonsteroidal anti-inflammatory drugs, take daily vitamin supplements (Table 3⁷), and continue lifestyle modifications for weight loss. Patients should delay pregnancy for at least 12 to 24 months after surgery.

EVIDENCE SUMMARY

Patients may require repeated adjustments to lipid-lowering, antihypertensive, diabetes, and thyroid medications.⁷ Changes in medication absorption, distribution, and metabolism after metabolic surgery are highly variable, and evidence does not support routine changes in medication administration.¹⁷ If physicians suspect medication malabsorption or if patients experience difficulty swallowing pills, switching to liquid, soft-gel, crushed tablet, or non-oral medications should be considered.^{7,17} Patients should avoid

FIGURE 4



Adjustable gastric banding involves laparoscopically inserting a hollow, flexible silicone band, which is inflated with saline to create a small gastric pouch. This ring can be tightened or loosened via a subcutaneous access port.

Illustration by Dave Klemm

Reprinted with permission from Schroeder R, Harrison TD, McGraw SL. Treatment of adult obesity with bariatric surgery. Am Fam Physician. 2016;93(1):34.

TABLE 1

Selection and Exclusion Criteria for Metabolic Surgery

Selection criteria

Able to adhere to postoperative care plan (e.g., follow-up visits and tests, medical management, use of dietary supplements)

Class 1 obesity (BMI of 30 to 34.9 kg per m²) and diabetes mellitus with inadequate glycemic control despite optimal lifestyle and medical therapy

Class 2 obesity (BMI ≥ 35 kg per m²) and at least 1 severe, obesity-related condition (type 2 diabetes, prediabetes, hypertension, nonalcoholic fatty liver disease, obstructive sleep apnea, osteoarthritis of the knee or hip, and urinary stress incontinence; consider for obesity-hypoventilation syndrome, idiopathic intracranial hypertension, gastroesophageal reflux disease, severe venous stasis, impaired mobility due to obesity, and considerably impaired quality of life)

Class 3 obesity (BMI ≥ 40 kg per m²)

Exclusion criteria

Cardiopulmonary disease that would make the risk prohibitive

Current illicit drug or alcohol use

Current tobacco use

Lack of comprehension of risks, benefits, expected outcomes, alternatives, and required lifestyle changes

Reversible endocrine or other disorders that can cause obesity

Uncontrolled severe psychiatric illness

BMI = body mass index.

Information from reference 7.

TABLE 2

Preoperative Evaluation for Metabolic Surgery

Recommend

Age- and risk-appropriate cancer screening

Complete history and physical examination (e.g., assess obesity-related conditions, weight-loss history, commitment to postsurgical lifestyle modifications, exclusions for surgery)

Discontinue estrogen medications preoperatively (1 cycle for oral contraceptives, 3 weeks for hormone therapy) to decrease risk of thrombosis

Laboratory studies* (e.g., A1C, complete blood count, complete metabolic profile, folic acid, iron, lipid profile, prothrombin time, urinalysis, vitamin B₁₂, 25-hydroxyvitamin D, additional evaluation as indicated) to identify and optimize the most common obesity-related and postoperative conditions

Nutrition evaluation

Pregnancy counseling†

Psychosocial and behavioral evaluations

Tobacco cessation counseling for optimal wound healing

Additional evaluations to consider

Cardiopulmonary (e.g., polysomnography, electrocardiography, additional evaluation if cardiac disease or pulmonary hypertension suspected)

Gastrointestinal (*Helicobacter pylori* screening in high-prevalence areas; gall bladder evaluation, upper endoscopy if clinically indicated)

Liver ultrasonography if elevated liver function tests

Thiamine level before malabsorptive procedure

Thyroid-stimulating hormone and testing for syndromic causes of obesity only if clinically indicated

*—Results useful in identification and optimization of the most common obesity-related and postoperative conditions.

†—Pregnancy is not recommended for 12 to 24 months postoperatively because of the degree of weight loss in the first year.

Information from reference 7.

nonsteroidal anti-inflammatory drugs because of increased risk of anastomotic ulcerations.⁷

The American Society for Metabolic and Bariatric Surgery and the American College of Surgeons mandate that surgical centers follow patients for the first year after surgery and attempt to follow patients annually for life.¹⁸ However, patients may request primary care management. Quarterly assessment of nutritional status and supplementation needs, food intolerances, and symptoms should occur for the first postsurgical year (Table 4).⁷ Vitamin supplementation is required throughout the patient's lifetime, and annual metabolic and nutritional monitoring is recommended (Table 3).⁷

Slow progression of diet from clear liquids to regular food is necessary over the first four to six weeks postoperatively.⁷ After surgery, each meal should begin with protein to ensure adequate intake (at least 60 g [2.14 oz] per day) to minimize the loss of lean body mass.⁷ Food intolerances are patient specific, but very dry foods, breads, and fibrous vegetables are often problematic. Fluids should be avoided for 15 to 30 minutes before, during, and after meals because food mixed

with fluid will pass easily through the stomach, diminishing the sensation of fullness. Carbonated beverages should be avoided because of the added gas.

Patients should avoid pregnancy for 12 to 24 months after metabolic surgery because of an increased risk of adverse outcomes.^{7,19} There is insufficient evidence on the effectiveness of oral, implanted, or injectable contraceptives to recommend a specific method.¹⁹

Continued lifestyle modifications, including regular physical activity and behavioral interventions to address food impulse control, are necessary. Ongoing participation in postsurgical support groups, self-monitoring, and use of mobile technology are highly recommended.⁷

TABLE 3

Supplementation After Metabolic Surgery

Supplement	Recommended dosage	Comments
Calcium citrate	1,200 to 1,500 mg per day	Split doses; monitor for osteoporosis
Elemental iron	45 to 60 mg per day (including multivitamin)	Take iron and calcium supplements at least 2 hours apart
Multivitamin with minerals (including iron, folic acid, copper, selenium, thiamine, and zinc)	2 per day	Liquid or chewable for 3 to 6 months, bariatric vitamin is preferred
Vitamin B ₁₂	1,000 mcg per day	Sublingual, subcutaneous, intramuscular, or oral if adequately absorbed
Vitamin D ₃	At least 3,000 IU per day	Titrate to 25-hydroxy-vitamin D level > 30 ng per mL (74.88 nmol per L)

Information from reference 7.

What Are the Long-Term Benefits of Metabolic Surgery?

Although most patients who have metabolic surgery will not achieve a BMI of less than 25 kg per m², patients generally experience significant weight loss.²⁰⁻²⁴ These patients have an average life expectancy 2.4 to three years longer than similar nonsurgical patients.²⁴ Outcomes of metabolic surgery are summarized in Table 5.^{7,20-44}

EVIDENCE SUMMARY

Over the first three years after surgery, patients lose 30 to 50 kg (66 to 110 lb) on average, corresponding to a BMI decrease of 11 to 17 kg per m² and a 60% to 70% reduction in excess body weight (a 20% to 30% reduction in total body weight).^{20-23,25,26} Most patients will experience some degree of weight regain between three and 10 years after surgery and stabilize at an average loss of 17% to 30% of excess body weight.^{24,27} Roux-en-Y gastric bypass generally leads to greater weight loss than sleeve gastrectomy during the first two postsurgical years, but it is unclear whether a significant long-term difference occurs.²³ Limited evidence suggests that single anastomosis duodenal-ileal bypass with sleeve is associated with greater weight loss and improved weight maintenance compared with other procedures.^{45,46}

Metabolic surgery results in significant improvement in obesity-related conditions. Approximately 70% of surgical patients achieve remission of type 2 diabetes, and about 38% of surgical patients maintain remission at 10 years.^{27,28} Even without remission, approximately 90% of surgical patients experience improvement in diabetes control and have decreased risk of macrovascular and microvascular

complications.²⁹⁻³¹ No difference has been found between procedures in the rate of remission or improved control of type 2 diabetes, dyslipidemia, or obstructive sleep apnea.³²

Patients who have undergone metabolic surgery are less likely to develop new-onset type 2 diabetes; hypertension; obstructive sleep apnea; dyslipidemia; ischemic heart disease; cardiac failure; melanoma; or breast, colon, endometrial, and pancreatic cancers.^{33,47,48} After the initial postoperative period, mortality rates among patients who have had metabolic surgery are significantly lower than nonsurgical control patients.^{20,24,25,33-35,49} Mortality rates remain lower 20 years postsurgery.²⁴

Patients who have metabolic surgery experience improved quality-of-life scores compared with those who have nonsurgical treatments for obesity, with sustained improvement at 10 years postsurgery.^{50,51}

Metabolic surgery is cost-effective over a 10-year time horizon and cost saving over a lifetime, resulting from

TABLE 4

Metabolic Surgery: Postsurgical Monitoring and Follow-up

- Adjust postoperative medications as needed
- Avoid nonsteroidal anti-inflammatory drugs
- Avoid pregnancy for 12 to 24 months
- Consider gout and gallstone prophylaxis in appropriate patients
- Measure bone density with dual energy x-ray absorptiometry at 2 years postsurgery
- Monitor progress with weight loss and adherence to dietary, behavioral, and physical activity recommendations
- Obtain quarterly laboratory studies for first year (A1C, complete blood count, complete metabolic profile, iron, vitamin B₁₂)
- Perform annual laboratory studies (complete blood count, complete metabolic profile, copper and ceruloplasmin iron studies, intact parathyroid hormone level, lipid profile, thiamine, thyroid-stimulating hormone, vitamin A, vitamin B₁₂, zinc, 25-hydroxyvitamin D)*

*—Routine screening of selenium, vitamin K, and vitamin E is not recommended. Consider testing for selenium if patients have unexplained anemia or fatigue, persistent diarrhea, cardiomyopathy, or metabolic bone disease. Consider testing for vitamin K if patients have excessive bleeding or bruising. Consider screening for vitamin E if patients have hemolytic anemia or neuromuscular or ophthalmologic symptoms.

Information from reference 7.

decreased medication costs, improvement in obesity-related conditions, and indirect costs due to productivity.⁴⁹

What Adverse Outcomes Are Common After Metabolic Surgery?

Surgical complications, nutritional deficiencies, bone density loss, dumping syndrome, gastroesophageal reflux disease (GERD), and loose skin are common adverse outcomes after metabolic surgery.

EVIDENCE SUMMARY

Approximately 15% of patients experience early surgical complications, including bleeding, stomal stenosis, anastomotic leak, vomiting, infection, ileus, wound dehiscence, pulmonary embolism, and electrolyte abnormalities.^{20,24} Reoperation is required in 3% to 7% of patients.^{20,24}

Cold intolerance, hair loss, and fatigue are common during the first year because of rapid weight loss, but these adverse effects diminish as weight loss stabilizes.

Malabsorptive procedures, including Roux-en-Y gastric bypass and single anastomosis duodenal-ileal bypass with sleeve, are associated with a higher risk of nutritional deficiencies than other procedures, particularly for patients who do not follow vitamin supplementation recommendations. Anemia affects 17% of patients who have sleeve gastrectomy and 45% to 50% of patients who have Roux-en-Y gastric bypass; anemia can be associated with deficiencies of iron, vitamin B₁₂, folate, copper, selenium, and zinc.⁵² Notably, patients who have sleeve gastrectomy are at risk of vitamin B₁₂ deficiency due to a decrease in intrinsic factor-producing parietal cells.⁵² Deficiencies of vitamins B₁ (thiamine), A, D, E, K, and protein may also occur.⁵²

Bone density loss affects 8% to 13% of patients who have metabolic surgery.⁵² This is likely multifactorial from calcium deficiency, vitamin D deficiency, and adaptive bone unloading from weight loss. Initial treatment involves correction of vitamin D and calcium deficiencies.⁵³ If pharmacotherapy is indicated after correcting deficiencies, parenteral therapy is preferred because oral bisphosphonates increase the risk of anastomotic ulceration.⁵³

Symptoms of dumping syndrome occur in up to 40% of patients after metabolic surgery.⁵⁴ Early dumping syndrome is caused by rapid passage of nutrients into the small bowel, resulting in intestinal hormonal release and fluid shift. Symptoms occur within one hour of eating and include abdominal pain, diarrhea, bloating, nausea, flushing, palpitations, sweating, tachycardia, hypotension, and syncope.⁵⁴ Late dumping syndrome is caused by rapid absorption of carbohydrates, causing exaggerated insulin secretion. This results in hypoglycemia one to three hours after eating.⁵⁴ Treatment includes eating small, frequent meals; avoiding fluids with meals; and avoiding rapidly absorbed sugars.⁵⁴ If this is not effective, acarbose (Precose) may be added to slow carbohydrate digestion.⁵⁴ Other treatment options include somatostatin analogues and surgical revisions.⁵⁴

GERD may improve with weight loss but can worsen with decreased stomach size. Compared with Roux-en-Y gastric bypass, sleeve gastrectomy is less likely to improve GERD^{32,55} and is five times more likely to result in new-onset GERD

TABLE 5

Comparison of Outcomes for Metabolic Procedures

Outcome	Overall	Sleeve gastrectomy	Roux-en-Y gastric bypass
Excess body weight lost postsurgery	Average*		
1 to 2 years	60% to 70%	33% to 85%	48% to 85%
5 years	50% to 60%	46% to 66%	53% to 77%
10 years	50%		
Idiopathic intracranial hypertension	90% resolution of headache; 100% resolution of papilledema		
Mortality			
< 90 days	0.2% to 0.3%		
2 to 15 years	30% to 45% lower than nonsurgical controls		
> 20 years	23% lower than nonsurgical controls		
Obstructive sleep apnea	Decrease in Apnea-Hypopnea Index by 29 per hour		
Remission of hyperlipidemia	60% to 82%		
Remission of hypertension	17% to 49%		
Remission of type 2 diabetes mellitus			
1 to 2 years	72% to 80%	56% to 68%	56% to 84%
5 years	50% to 70%		
10 to 15 years	30% to 38%		
Resolution of urinary stress incontinence	47%		

*—Excess body weight is the total preoperative weight minus ideal weight.

Information from references 7 and 20-44.

postoperatively.⁵⁵ Patients with an adjustable gastric band also commonly present with GERD symptoms. The first therapeutic step is to loosen the band. If no improvement in GERD symptoms occurs, the band may need to be removed, with or without a revision to another metabolic procedure.

Loose skin is a result of significant weight loss and affects approximately 84% of patients who have had metabolic surgery.⁵⁶ Complications include irritation, fungal infections, difficulty finding clothing, patient perception of unattractiveness, and discomfort during exercise.⁵⁶ About 20% of patients undergo body-contouring surgery.⁵⁷ Approximately 2% of patients regret having metabolic surgery.⁵⁶

Although modest weight regain is common, some patients experience more weight regain than expected. Etiology includes nutritional indiscretion, mental health concerns, metabolic alterations, physical inactivity, and anatomic surgical failure.^{10,58,59}

This article updates previous articles on this topic by Schroeder, et al.,⁸ and Schroeder, et al.⁶⁰

Data Sources: The following resources were reviewed: the Agency for Healthcare Research and Quality, the Cochrane Database of Systematic Reviews, and the U.S. Preventive Services Task Force. References from key articles were searched, as were references from Essential Evidence Plus. In addition, a PubMed search was performed using key words obesity, metabolic surgery, bariatric surgery, and diabetes. Search dates: February 10, 2021; June 25, 2021; and December 13, 2021.

The Authors

ELAINE SEATON BANERJEE, MD, MPH, is an assistant professor at the University of South Florida Morsani College of Medicine, Tampa, in collaboration with the Department of Family Medicine at Lehigh Valley Health Network, Allentown, Pa.

ROBIN SCHROEDER, MD, is an associate professor in the Department of Family Medicine at the University of South Florida Morsani College of Medicine, and an obesity medicine specialist at the Weight Management Center at Lehigh Valley Health Network.

T. DANIEL HARRISON, DO, is the vice chair in the Department of Surgery and a metabolic surgeon at the Weight Management Center at Lehigh Valley Health Network.

Address correspondence to Elaine Seaton Banerjee, MD, MPH, Lehigh Valley Health Network, 250 Cetronia Rd., Ste. 115, Allentown, PA 18104 (email: elaine_s.banerjee@lvhn.org). Reprints are not available from the authors.

References

- Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. *Cochrane Database Syst Rev*. 2014;(8):CD003641.
- Hales CM, Carroll MD, Fryar CD, et al.; Centers for Disease Control and Prevention. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS data brief, no. 360. February 2020. Accessed June 15, 2021. <https://www.cdc.gov/nchs/products/databriefs/db360.htm>
- Strategies to Overcome and Prevent (STOP) Obesity Alliance. Weight can't wait. October 2020. Accessed June 15, 2021. <https://stop.publichealth.gwu.edu/sites/stop.publichealth.gwu.edu/files/WCW%20Guide/WCW%20-%20Guide%20for%20the%20Management%20of%20Obesity%20in%20the%20Primary%20Care%20Setting.pdf>
- Obesity Action Coalition. Obesity treatments: What is obesity treatment? Accessed June 15, 2021. <https://www.obesityaction.org/obesity-treatments/what-is-obesity-treatment/>
- Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2013;347:f5934.
- American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers, 2011–2019. March 2021. Accessed June 16, 2021. <https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers>
- Mechanick JL, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures—2019 update. *Endocr Pract*. 2019;25(12):1346–1359.
- Schroeder R, Harrison TD, McGraw SL. Treatment of adult obesity with bariatric surgery. *Am Fam Physician*. 2016;93(1):31–37. Accessed October 26, 2021. <https://www.aafp.org/afp/2016/0101/p31.html>
- Kallies K, Rogers AM; American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery updated statement on single-anastomosis duodenal switch. *Surg Obes Relat Dis*. 2020;16(7):825–830.
- Coblijn UK, Verveld CJ, van Wagenveld BA, et al. Laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy as revisional procedure after adjustable gastric band—a systematic review. *Obes Surg*. 2013;23(11):1899–1914.
- Cho YM. A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery [published correction appears in *Diabetes Metab J*. 2015;39(2):175]. *Diabetes Metab J*. 2014;38(6):406–415.
- Khosravi-Largani M, Nojomi M, Aghili R, et al. Evaluation of all types of metabolic bariatric surgery and its consequences: a systematic review and meta-analysis. *Obes Surg*. 2019;29(2):651–690.
- Department of Health and Human Services; Centers for Disease Control and Prevention. Body mass index: considerations for practitioners. Accessed September 21, 2021. <https://www.cdc.gov/obesity/downloads/bmi-for-practitioners.pdf>
- Giordano S, Victorzon M. The impact of preoperative weight loss before laparoscopic gastric bypass. *Obes Surg*. 2014;24(5):669–674.
- Anderin C, Gustafsson UO, Heijbel N, et al. Weight loss before bariatric surgery and postoperative complications: data from the Scandinavian Obesity Registry (SOREG). *Ann Surg*. 2015;261(5):909–913.
- Jamal MK, DeMaria EJ, Johnson JM, et al. Insurance-mandated preoperative dietary counseling does not improve outcome and increases dropout rates in patients considering gastric bypass surgery for morbid obesity. *Surg Obes Relat Dis*. 2006;2(2):122–127.
- Bland CM, Quidley AM, Love BL, et al. Long-term pharmacotherapy considerations in the bariatric surgery patient. *Am J Health Syst Pharm*. 2016;73(16):1230–1242.
- American Society for Metabolic and Bariatric Surgery; American College of Surgeons. Optimal resources for metabolic and bariatric surgery: 2019 standards. Accessed December 13, 2021. https://www.facs.org/media/fuhte1t/2022_cm_mbsaqip_standards_final_linked-toc.pdf
- Kominiarek MA, Jungheim ES, Hoeger KM, et al. American Society for Metabolic and Bariatric Surgery position statement on the impact of obesity and obesity treatment on fertility and fertility therapy; endorsed by the American College of Obstetricians and Gynecologists and the Obesity Society. *Surg Obes Relat Dis*. 2017;13(5):750–757.

20. Chang S-H, Stoll CRT, Song J, et al. The effectiveness and risks of bariatric surgery. *JAMA Surg*. 2014;149(3):275-287.
21. Puzifferri N, Roshek TB III, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. *JAMA*. 2014;312(9):934-942.
22. Courcoulas AP, Christian NJ, Belle SH, et al.; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. *JAMA*. 2013;310(22):2416-2425.
23. Yip S, Plank LD, Murphy R. Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes. *Obes Surg*. 2013;23(12):1994-2003.
24. Carlsson LMS, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish Obese Subjects study. *N Engl J Med*. 2020;383(16):1535-1543.
25. Sjöström L, Narbro K, Sjöström CD, et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med*. 2007;357(8):741-752.
26. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. *N Engl J Med*. 2014;370(21):2002-2013.
27. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes. *Lancet*. 2021;397(10271):293-304.
28. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA*. 2014;311(22):2297-2304.
29. Yu J, Zhou X, Li L, et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. *Obes Surg*. 2015;25(1):143-158.
30. Billeter AT, Eichel S, Scheurlen KM, et al. Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes. *Surg Obes Relat Dis*. 2019;15(7):1197-1210.
31. Billeter AT, Scheurlen KM, Probst P, et al. Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. *Br J Surg*. 2018;105(3):168-181.
32. Yang P, Chen B, Xiang S, et al. Long-term outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass for morbid obesity: results from a meta-analysis of randomized controlled trials. *Surg Obes Relat Dis*. 2019;15(4):546-555.
33. Wiggins T, Guidozzi N, Welbourn R, et al. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. *PLoS Med*. 2020;17(7):e1003206.
34. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. *N Engl J Med*. 2007;357(8):753-761.
35. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. *JAMA*. 2015;313(1):62-70.
36. Davies SW, Elfird JT, Guidry CA, et al. Long-term diabetic response to gastric bypass. *J Surg Res*. 2014;190(2):498-503.
37. Manfield JH, Yu KK-H, Efthimiou E, et al. Bariatric surgery for non-surgical weight loss for idiopathic intracranial hypertension? A systematic review and comparison of meta-analyses. *Obes Surg*. 2017;27(2):513-521.
38. Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. *Obes Surg*. 2015;25(12):2280-2289.
39. Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. *Surg Obes Relat Dis*. 2019;15(3):502-511.
40. Ashrafian H, Toma T, Rowland SP, et al. Bariatric surgery or non-surgical weight loss for obstructive sleep apnoea? A systematic review and comparison of meta-analyses. *Obes Surg*. 2015;25(7):1239-1250.
41. Hacken B, Rogers A, Chinchilli V, et al. Improvement in knee osteoarthritis pain and function following bariatric surgery: 5-year follow-up. *Surg Obes Relat Dis*. 2019;15(6):979-984.
42. Lee Y, Yu J, Tikkinen KAO, et al. The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis. *BJU Int*. 2019;124(6):917-934.
43. Li Y-J, Han Y, He B. Effects of bariatric surgery on obese polycystic ovary syndrome: a systematic review and meta-analysis. *Surg Obes Relat Dis*. 2019;15(6):942-950.
44. Bañares SJ, Real LR, Segovia JC, et al. Evaluation of quality of life, weight loss, and evolution of comorbidities at 6 years after bariatric surgery. *Endocrinol Diabetes Nutr (Engl ed)*. 2021;68(7):501-508.
45. Surve A, Cottam D, Medlin W, et al. Long-term outcomes of primary single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). *Surg Obes Relat Dis*. 2020;16(11):1638-1646.
46. Chen G, Zhang G-X, Peng B-Q, et al. Roux-en-Y gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis. *Obes Surg*. 2021;31(7):3303-3311.
47. Schauer DP, Feigelson HS, Koebnick C, et al. Bariatric surgery and the risk of cancer in a large multisite cohort. *Ann Surg*. 2019;269(1):95-101.
48. Taube M, Peltonen M, Sjöholm K, et al. Association of bariatric surgery with skin cancer incidence in adults with obesity: a nonrandomized controlled trial. *JAMA Dermatol*. 2020;156(1):38-43.
49. Xia Q, Campbell JA, Ahmad H, et al. Bariatric surgery is a cost-saving treatment of obesity—a comprehensive meta-analysis and updated systematic review of health economic evaluations of bariatric surgery. *Obes Rev*. 2020;21(1):e12932.
50. Raaijmakers LCH, Pouwels S, Thomassen SEM, et al. Quality of life and bariatric surgery: a systematic review of short- and long-term results and comparison with community norms. *Eur J Clin Nutr*. 2017;71(4):441-449.
51. Hachem A, Brennan L. Quality of life outcomes of bariatric surgery: a systematic review. *Obes Surg*. 2016;26(2):395-409.
52. Lupoli R, Lembo E, Saldalamacchia G, et al. Bariatric surgery and long-term nutritional issues. *World J Diabetes*. 2017;8(11):464-474.
53. Krez AN, Stein EM. The skeletal consequences of bariatric surgery. *Curr Osteoporos Rep*. 2020;18(3):262-272.
54. Tack J, Deloof E. Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies. *Best Pract Res Clin Gastroenterol*. 2014;28(4):741-749.
55. Gu L, Chen B, Du N, et al. Relationship between bariatric surgery and gastroesophageal reflux disease: a systematic review and meta-analysis. *Obes Surg*. 2019;29(12):4105-4113.
56. Björserud C, Olbers T, Fagevik Olsén M. Patients' experience of surplus skin after laparoscopic gastric bypass. *Obes Surg*. 2011;21(3):273-277.
57. Kitzinger HB, Abayev S, Pittermann A, et al. The prevalence of body contouring surgery after gastric bypass surgery. *Obes Surg*. 2012;22(1):8-12.
58. Cooper TC, Simmons EB, Webb K, et al. Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery. *Obes Surg*. 2015;25(8):1474-1481.
59. Karmali S, Brar B, Shi X, et al. Weight recidivism post-bariatric surgery: a systematic review. *Obes Surg*. 2013;23(11):1922-1933.
60. Schroeder R, Garrison JM Jr, Johnson MS. Treatment of adult obesity with bariatric surgery. *Am Fam Physician*. 2011;84(7):805-814. Accessed October 26, 2021. <https://www.aafp.org/afp/2011/1001/p805.html>